Redeye: Redeye Initiates Coverage of Corline Biomedical
Redeye initiates coverage of Corline Biomedical, a Swedish medtech/biotech company specialising in coating solutions for the medical technology industry and transplantation clinics. With its partner Kardium expected to enter the commercial stage in 2026e, we anticipate a significant sales uptick. Our fair value range suggests a substantial upside, supported by several key catalysts linked to Kardium’s product launch.
Read more and download the Research Report.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/